PowerPoint slides on pharmacodynamics: dose-effect relationship and related concepts

Dr. Edwin Jackson, from the ASPET Division of Cardiovascular Pharmacology, prepared the following PowerPoint lecture on pharmacodynamics, mainly about the dose-effect relationship. The approach is very interesting since its quite clear and simple, but still accurate and thorough. Dose-effect relationships What determines the dose-effect relationship? What is the relationship between [drug] and [drug receptor]? What […]

Free download: pharmacology flash cards. Antibiotics, antivirals, antiretrovirals and antitubercular drugs

The Department of Pharmacology of the University of Utah has developed some study aids available at their website. Below is the summary of the file on antibiotics and related drugs, and the link to the original file. Antibacterial Drugs Sulfonamides: Sulfisoxazole (Gantrisin), Sulfamethoxazole (Gantanol), Sulfadiazine, Sulfasalazine (Azulfidine), Sulfacetamide sodium (Sulamyd Sodium) Trimethoprim-Sulfamethoxazole (Bactrim, Septra) Chloramphenicol […]

PowerPoint review: levocetirizine (Xyzal), a third generation antihistamine

This presentation reviews some aspects of the third generation antihistamine Levocetirizine (Xyzal), the active enantiomer of cetirizine (second generation). What do you think? Is Levocetirizine worth it or not? Personally, I don’t see many advantages over other histamine blockers considering pricing factors. Technorati : , Xyzal, levocetirizine, third generation antihistamine

Antitubercular and antiviral (HSV, CMV, influenza) drugs: NCLEX video review

This video is targeted to nurses and nursing students, as a pharmacology review previous to the NCLEX exam. It reviews the following drug classes: Antimycobacterial (antitubercular) drugs: isoniazid, pyrazinamide, rifampin, ethambutol Drugs for the treatment of herpesvirus infections: acyclovir famciclovir Drugs for the treatment of influenza:amantadine, rimantadine, zanamivir, oseltamivir Drugs for the treatment of citomegalovirus […]

Xigris (Drotrecogin alfa activated): concerns of serious bleeding and increased death trigger FDA safety review

On February 4th, 2009 the FDA announced an ongoing safety review of Xigris (Drotrecogin alfa [activated]). An introduction from Wikipedia: Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C ( rhAPC) that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class […]

Animation on histamine release and antihistamines mechanism of action

In this 3-D animation, oriented to the general public, we can see the process of histamine release by mast cell starting from the exposure to the allergen: This image shows the same process: H1 blockers are a class of widely prescribed drugs, here an excerpt of its pharmacodynamics (Source: Katzung’s Basic and Clinical Pharmacology) A. […]

Pharmaceutical marketing in the web 2.0 era

Melissa Sweet, Health Journalist, published an article on Australian Prescriber about the applications of web 2.0 tools in drug marketing by pharmaceutical companies. Pharmaceutical companies are capitalising on the advent of the internet and the development of new media forms to promote their products. Electronic detailing, interactive websites, email prompts and viral marketing campaigns using […]

Methylnaltrexone (Relistor): clinical updates from two independent sources

Methylnaltrexone (Relistor) is a peripherally-acting μ-opioid antagonist used for the treatment of opioid induced constipation. Two independent organizations have recently published updated clinical information on this drug: Australian Prescriber. New drugs: Methylnaltrexone Health Canada. Summary Basis of Decision (SBD) RELISTOR The Scottish Medicines Consortium also reviewed Relistor in January 2009.

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos